Novartis continues its blitz on NASH deals, grabbing an exclusive tie-up in race to develop cocktails
Five months ago Novartis $NVS rocked Conatus’ world with a collaboration deal for its NASH drug emricasan. The biotech’s stock quadrupled in value. And it got another boost today as the pharma giant followed up with its announcement that it is indeed picking up the exclusive worldwide option for the drug, chipping in an extra $7 million to seal the deal.
Conatus stock $CNAT is up 13% in pre-market trading and the micro biotech has seen its market cap break through the $200 million mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.